Is Sandu Pharma. overvalued or undervalued?

As of 19 November 2025, Sandu Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 25.21, an EV to EBITDA of 13.51, and a Price to Book Value of 0.94, which suggest that the stock is trading at a reasonable price relative to its earnings and book value.
In comparison to its peers, Sandu Pharma's valuation appears favorable. For instance, Elitecon International is categorized as very expensive with a PE Ratio of 265.8, while PTC India, deemed very attractive, has a significantly lower PE Ratio of 7.5. Despite recent underperformance, with a year-to-date return of -28.92% compared to the Sensex's 9.02%, the attractive valuation grade and competitive ratios position Sandu Pharma as a potential buying opportunity in the pharmaceuticals and biotechnology sector.